Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab Every 4 Weeks vs Every 12 Weeks in Bone Metastases
NCT02051218Phase 3Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jul 2014
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of denosumab in bone metastases, sponsored by Swiss Group for Clinical Cancer Research. Started Jul 2014; status: terminated.
02
Drugs
denosumab
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT02051218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02051218.